Skip to main content
SpringerLink
Log in

Influence of different viscosity grade cellulose-based polymers on the development of valsartan controlled release tablets

  • Original Paper
  • Published:
Polymer Bulletin Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

This work is based on formulating and optimizing controlled release (CR) valsartan (160 mg) tablets using different viscosity grades of the cellulosic polymer. The objective was to develop an effective once-daily drug delivery system of this cardiovascular agent. Central composite design was used for designing the formulations. Polymers used were Methocel® K4M, K15M and K100M. Compatibility of excipients with active was studied through FT-IR. Micromeritic properties were determined and formulations exhibiting appropriate flow characteristics were compressed. Swelling behavior and in vitro buoyancy effect were studied and response surface curves were constructed to optimize the formulation. Multi-point dissolution profiles of valsartan CR tablets at pH 1.2, 4.5 and 6.8 were obtained. Model-dependent and model-independent methods were performed including f2, stability test as per ICH guidelines and ANOVA. FT-IR studies revealed the compatibility of valsartan with all excipients. Formulation K4T9 (containing 25% K4M polymer) was selected to be the best optimized trial, based on physical properties and controlled release profile (23% at 4 h, 82% at 16 h and 100% at 24 h). Results of buoyancy and swelling behavior indicated that HPMC-K4M polymer exhibited excellent floating lag time and swelling indexes. In vitro drug release kinetics showed that formulation K4T9 displayed Korsmeyer–Peppas drug release pattern with r value > 0.99. The manufacturing process of K4T9 was also found to be reproducible with a shelf life period of 41 and 36 months at room temperature and accelerated conditions, respectively. Valsartan CR matrix-based formulation was successfully prepared with Methocel K4M retardant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Chien Y (1992) Oral drug delivery and delivery systems. In: Chien YW (ed) Novel drug delivery systems. Marcel Dekker, New York

    Google Scholar 

  2. Vyas SP, Khar RK (2002) Controlled drug delivery concepts and advances. Vallabh Prakashan 1:411–447

    Google Scholar 

  3. Shah SU, Shah KU, Rehman A, Khan GM (2011) Investigating the in vitro drug release kinetics from controlled release diclofenac potassium-ethocel matrix tablets and the influence of co-excipients on drug release patterns. Pak J Pharm Sci 24:183–192

    CAS  PubMed  Google Scholar 

  4. Bayomi MA, Al-Suwayeh SA, El-Helw A-RM (2001) Excipient–excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation. Drug Dev Ind Pharm 27(6):499–506

    CAS  PubMed  Google Scholar 

  5. Baveja S, Rao KR, Devi KP (1988) Relationship between gum content and half-life of soluble β blockers from hydrophilic matrix tablets. Int J Pharm 47(1–3):133–139

    CAS  Google Scholar 

  6. Colombo P, Bettini R, Santi P, De Ascentiis A, Peppas N (1996) Analysis of the swelling and release mechanisms from drug delivery systems with emphasis on drug solubility and water transport. J Control Release 39(2–3):231–237

    CAS  Google Scholar 

  7. Kanakagiri D, Omprakash H, Kumar KM, Vishwanadham Y (2017) Formulation and evaluation of pantoprazole delayed release tablets using Eudragit L30D55. Res J Pharm Technol 10(2):421–425

    Google Scholar 

  8. Pandey SP, Shukla T, Dhote VK, Mishra DK, Maheshwari R, Tekade RK (2019) Use of polymers in controlled release of active agents. In: Basic fundamentals of drug delivery. Elsevier, pp 113–172

  9. Siepmann J, Peppas N (2012) Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 64:163–174

    Google Scholar 

  10. Chaerunisaa AY, Ali R, Dashevskiy A (2019) Release adjustment of two drugs with different solubility combined in a matrix tablet. AAPS PharmSciTech 20(4):142

    PubMed  Google Scholar 

  11. Wang S, Wen H, Li P, Cui M, Sun W, Wang H, Liu H, Li S, Pan W, Yang X (2019) Formulation and evaluation of gastric-floating controlled release tablets of Ginkgolides. J Drug Deliv Sci Technol 51:7–17

    CAS  Google Scholar 

  12. Rebouh S, Lefnaoui S, Bouhedda M, Yahoum MM, Hanini S (2019) Neuro-fuzzy modeling of ibuprofen-sustained release from tablets based on different cellulose derivatives. Drug Deliv Transl Res 9(1):162–177

    CAS  PubMed  Google Scholar 

  13. Sweetman S (2005) Martindale: the complete drug reference, 34th edn. Pharmaceutical Press, London, pp 900–901

    Google Scholar 

  14. Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, Fitzsimmons S (1996) The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 18(5):797–810

    CAS  PubMed  Google Scholar 

  15. IBM (2019) Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com/

  16. Mahajan P, Mahajan S, Mishra D (2011) Valsartan release from sustained release matrix tablet and effect of cellulose derivatives. Int J Pharm Life Sci 2(1):521–530

    CAS  Google Scholar 

  17. Nayak UY, Shavi GV, Nayak Y, Averinen RK, Mutalik S, Reddy SM, Gupta PD, Udupa N (2009) Chronotherapeutic drug delivery for early morning surge in blood pressure: a programmable delivery system. J Control Release 136(2):125–131

    CAS  PubMed  Google Scholar 

  18. Sokar M, Hanafy A, El-Kamel A, El-Gamal S (2013) Pulsatile core-in-cup valsartan tablet formulations: in vitro evaluation. Asian J Pharm Sci 8(4):234–243

    Google Scholar 

  19. Shah S, Patel R, Soniwala M, Chavda J (2015) Development and optimization of press coated tablets of release engineered valsartan for pulsatile delivery. Drug Dev Ind Pharm 41(11):1835–1846

    CAS  PubMed  Google Scholar 

  20. Liltorp K, Larsen TG, Willumsen B, Holm R (2011) Solid state compatibility studies with tablet excipients using non thermal methods. J Pharm Biomed Anal 55(3):424–428

    CAS  PubMed  Google Scholar 

  21. USP35-NF30 U (2012) United States Pharmacopeial. Rockville

  22. Commission USP (2013) USP36/NF31. US Pharmacopeia, Rockville

    Google Scholar 

  23. Cao Q-R, Choi Y-W, Cui J-H, Lee B-J (2005) Effect of solvents on physical properties and release characteristics of monolithic hydroxypropylmethylcellulose matrix granules and tablets. Arch Pharm Res 28(4):493–501

    CAS  PubMed  Google Scholar 

  24. Jiménez-Castellanos MR, Zia H, Rhodes CT (1994) Design and testing in vitro of a bioadhesive and floating drug delivery system for oral application. Int J Pharm 105(1):65–70

    Google Scholar 

  25. Costa P, Lobo JMS (2001) Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13(2):123–133

    CAS  Google Scholar 

  26. Shoaib MH, Siddiqi SAS, Yousuf RI, Zaheer K, Hanif M, Rehana S, Jabeen S (2010) Development and evaluation of hydrophilic colloid matrix of famotidine tablets. AAPS PharmSciTech 11(2):708–718

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Higuchi WI (1967) Diffusional models useful in biopharmaceutics: drug release rate processes. J Pharm Sci 56(3):315–324

    CAS  Google Scholar 

  28. Hixson A, Crowell J (1931) Dependence of reaction velocity upon surface and agitation. Ind Eng Chem 23(8):923–931

    CAS  Google Scholar 

  29. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA (1983) Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 15(1):25–35

    CAS  Google Scholar 

  30. Langenbucher F (1972) Letters to the editor: linearization of dissolution rate curves by the Weibull distribution. J Pharm Pharmacol 24(12):979–981

    CAS  PubMed  Google Scholar 

  31. Baker RW, Lonsdale HK (1974) Controlled release: mechanisms and rates. In: Tanquary AC, Lacey RE (eds) Controlled release of biologically active agents. Plenum Press, New York, pp 15–71

    Google Scholar 

  32. Guideline IHT (2003) Stability testing of new drug substances and products. Q1A (R2) Curr Step 4:1–24

    Google Scholar 

  33. Hanif M, Shoaib M, Rabia I, Iyad N, Ahmad K, Tariq A (2011) Formulation development and optimization of nimesulide tablets by central composit design and effect of surfactants on dissolution studies. J Pharm Res 4:2447–2452

    CAS  Google Scholar 

  34. Chopra S, Patil GV, Motwani SK (2007) Release modulating hydrophilic matrix systems of losartan potassium: optimization of formulation using statistical experimental design. Eur J Pharm Biopharm 66(1):73–82

    CAS  PubMed  Google Scholar 

  35. Cao Q-R, Liu Y, Xu W-J, Lee B-J, Yang M, Cui J-H (2012) Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique. Int J Pharm 434(1–2):325–333

    CAS  PubMed  Google Scholar 

  36. Tiţa B, Fuliaş A, Bandur G, Marian E, Tiţa D (2011) Compatibility study between ketoprofen and pharmaceutical excipients used in solid dosage forms. J Pharm Biomed Anal 56(2):221–227

    PubMed  Google Scholar 

  37. Verma RK, Garg S (2004) Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations. J Pharm Biomed Anal 35(3):449–458

    CAS  PubMed  Google Scholar 

  38. Verma RK, Garg S (2005) Selection of excipients for extended release formulations of glipizide through drug–excipient compatibility testing. J Pharm Biomed Anal 38(4):633–644

    CAS  PubMed  Google Scholar 

  39. Chella N, Tadikonda R (2015) Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs—a case study with valsartan. Drug Dev Ind Pharm 41(6):888–897

    CAS  PubMed  Google Scholar 

  40. Prescott JK, Barnum RA (2000) On powder flowability. Pharm Technol 24(10):60–85

    CAS  Google Scholar 

  41. Mendez R, Muzzio F, Velazquez C (2010) Study of the effects of feed frames on powder blend properties during the filling of tablet press dies. Powder Technol 200(3):105–116

    CAS  Google Scholar 

  42. Siddiqui A, Nazzal S (2007) Measurement of surface color as an expedient QC method for the detection of deviations in tablet hardness. Int J Pham 341(1–2):173–180

    CAS  Google Scholar 

  43. Tan I, Ahmad A, Hameed B (2008) Optimization of preparation conditions for activated carbons from coconut husk using response surface methodology. Chem Eng J 137(3):462–470

    CAS  Google Scholar 

  44. Myers RH, Montgomery DC, Anderson-Cook CM (2009) Response surface methodology: process and product optimization using designed experiments (Wiley series in probability and statistics). Wiley, New York

    Google Scholar 

  45. Wu X-G, Li G, Gao Y-L (2006) Optimization of the preparation of nalmefene-loaded sustained-release microspheres using central composite design. Chem Pharm Bull 54(7):977–981

    CAS  PubMed  Google Scholar 

  46. Nellore RV, Rekhi GS, Hussain AS, Tillman LG, Augsburger LL (1998) Development of metoprolol tartrate extended-release matrix tablet formulations for regulatory policy consideration. J Control Release 50(1–3):247–256

    CAS  PubMed  Google Scholar 

  47. Campos-Aldrete ME, Villafuerte-Robles L (1997) Influence of the viscosity grade and the particle size of HPMC on metronidazole release from matrix tablets. Eur J Pharm Biopharm 43(2):173–178

    CAS  Google Scholar 

  48. Huang Y-B, Tsai Y-H, Lee S-H, Chang J-S, Wu P-C (2005) Optimization of pH-independent release of nicardipine hydrochloride extended-release matrix tablets using response surface methodology. Int J Pharm 289(1–2):87–95

    CAS  PubMed  Google Scholar 

  49. Mandal U, Gowda V, Ghosh A, Selvan S, Solomon S, Pal TK (2007) Formulation and optimization of sustained release matrix tablet of metformin HCl 500 mg using response surface methodology. Yakugaku Zasshi 127(8):1281–1290

    CAS  PubMed  Google Scholar 

  50. Baumgartner S, Smid-Korbar J, Vrecer F, Kristl J (1998) Physical and technological parameters influencing floating properties of matrix tablets based on cellulose ethers. STP Pharma Sci 8(5):285–290

    CAS  Google Scholar 

  51. Wan LSC, Heng PWS, Wong LF (1995) Matrix swelling: a simple model describing extent of swelling of HPMC matrices. Int J Pharm 116(2):159–168

    CAS  Google Scholar 

  52. Nerurkar J, Jun H, Price J, Park M (2005) Controlled-release matrix tablets of ibuprofen using cellulose ethers and carrageenans: effect of formulation factors on dissolution rates. Eur J Pharm Biopharm 61(1–2):56–68

    CAS  PubMed  Google Scholar 

  53. Nagarwal RC, Ridhurkar DN, Pandit J (2010) In vitro release kinetics and bioavailability of gastroretentive cinnarizine hydrochloride tablet. AAPS PharmSciTech 11(1):294–303

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Patel A, Modasiya M, Shah D, Patel V (2009) Development and in vivo floating behavior of verapamil HCl intragastric floating tablets. AAPS PharmSciTech 10(1):310–315

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Ebube NK, Jones AB (2004) Sustained release of acetaminophen from a heterogeneous mixture of two hydrophilic non-ionic cellulose ether polymers. Int J Pharm 272(1–2):19–27

    CAS  PubMed  Google Scholar 

  56. Shanmugam S, Chakrahari R, Sundaramoorthy K, Ayyappan T, Vetrichelvan T (2011) Formulation and evaluation of sustained release matrix tablets of Losartan potassium. Int J PharmTech Res 3(1):526–534

    CAS  Google Scholar 

  57. Juarez-Soberanez D, Villafuerte-Robles LG (2011) 39/01 as excipient for gastroretentive metronidazole sustained delivery. Int J Pharm Pharm Sci 3(2):86–91

    CAS  Google Scholar 

  58. Merchant HA, Shoaib HM, Tazeen J, Yousuf RI (2006) Once-daily tablet formulation and in vitro release evaluation of cefpodoxime using hydroxypropyl methylcellulose: a technical note. AAPS PharmSciTech 7(3):E178–E183

    PubMed  PubMed Central  Google Scholar 

  59. Sankalia JM, Sankalia MG, Mashru RC (2008) Drug release and swelling kinetics of directly compressed glipizide sustained-release matrices: establishment of level A IVIVC. J Control Release 129(1):49–58

    CAS  PubMed  Google Scholar 

  60. LcS Koester, Ortega GG, Mayorga P, Bassani VL (2004) Mathematical evaluation of in vitro release profiles of hydroxypropylmethylcellulose matrix tablets containing carbamazepine associated to β-cyclodextrin. Eur J Pharm Biopharm 58(1):177–179

    Google Scholar 

  61. Papadopoulou V, Kosmidis K, Vlachou M, Macheras P (2006) On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm 309(1–2):44–50

    CAS  PubMed  Google Scholar 

  62. Peppas N (1985) Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60(4):110–1

    CAS  PubMed  Google Scholar 

  63. Rao GK, Mandapalli PK, Manthri R, Reddy VP (2013) Development and in vivo evaluation of gastroretentive delivery systems for cefuroxime axetil. Saudi Pharm J 21(1):53–59

    PubMed  Google Scholar 

  64. Tillotson JK (2004) Development and evaluation of extended-release bumetanide tablets. University of Cincinnati

  65. Bajaj S, Singla D, Sakhuja N (2012) Stability testing of pharmaceutical products. J Appl Pharm Sci 2:129–138

    Google Scholar 

  66. Júlio TA, Zâmara IF, Garcia JS, Trevisan MG (2013) Compatibility and stability of valsartan in a solid pharmaceutical formulation. Braz J Pharm Sci 49(4):645–651

    Google Scholar 

Download references

Author information

Author notes

  1. Sana Ghayas & Farah Khalid

    Present address: Department of Pharmaceutics, Faculty of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan

Authors and Affiliations

  1. Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan

    Sana Ghayas, Muhammad Harris Shoaib, Faaiza Qazi, Fatima Ramzan Ali & Madiha Maboos

  2. Department of Pharmaceutics, Faculty of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan

    Rabia Bushra

Authors
  1. Sana Ghayas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muhammad Harris Shoaib
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Faaiza Qazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rabia Bushra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fatima Ramzan Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Madiha Maboos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Farah Khalid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muhammad Harris Shoaib.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghayas, S., Shoaib, M.H., Qazi, F. et al. Influence of different viscosity grade cellulose-based polymers on the development of valsartan controlled release tablets. Polym. Bull. 77, 1281–1306 (2020). https://doi.org/10.1007/s00289-019-02802-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00289-019-02802-2

Keywords

Search

Navigation